Posterior Circulation Ischemic StrokeETP1-PCNCT07699029
Endovascular Treatment for Posterior Circulation Ischemic Stroke Post 1 Day （24 Hours）
A study testing Endovascular treatment combined with standard pharmacological treatment and Standard pharmacological treatment in people with Posterior Circulation Ischemic Stroke, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
Trial summary
To evaluate the efficacy and safety of endovascular therapy for posterior circulation ischemic stroke presenting more than 24 hours after symptom onset. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Posterior Circulation Ischemic Stroke
- What is being tested?
- Endovascular treatment combined with standard pharmacological treatment and Standard pharmacological treatment
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 244 participants
- Where
- 1 siteChina
- Study dates
- 16 Jul 2026to 1 Aug 2030
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years old
- Baseline NIHSS score of 4 or higher, maintained prior to randomization
- Stroke onset or more than 24 hours since the last known good state, but within 14 days
- CTA/MRA/DSA confirmed occlusion of the responsible vessel in basilar artery or intracranial segments of both vertebral arteries (V4)
- Modified Rankin Scale (mRS) score of 0 or 1 pre-stroke
- The subject or their legally authorized representative has signed the informed consent form for the study
Who cannot join
- Hemorrhage on CT or MRI
- Based on the judgment of the treating physician, the patient is considered unlikely to benefit from the trial (e.g., advanced dementia, severe pre-stroke disability (mRS ≥ 2), or high risk of early mortality)
- Major comorbidities that may interfere with outcome assessment and follow-up (e.g., severe heart failure, renal failure, etc.).
- Evidence of vascular recanalization prior to randomization
- Uncontrolled seizures at the time of stroke onset, if they interfere with obtaining an accurate baseline NIHSS
- Posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) < 6 on non-contrast CT or CT angiography source images or MR with diffusion-weighted imaging
Show all 20Show fewer
- Complete cerebellar infarct with significant mass effect and compression of the fourth ventricle,or bilateral thalamic infarction on CT or MRI
- Baseline platelet count <50,000/uL
- Severe, persistent hypertension (systolic blood pressure > 220 mmHg or diastolic blood pressure > 120 mmHg)
- Known hereditary or acquired bleeding disorders, coagulation factor deficiencies, or recent oral anticoagulant therapy with an International Normalized Ratio (INR) > 3
- Suspected purulent embolism, with a suspicion of bacterial endocarditis
- Known allergies to iodine, heparin, anesthetics, or other explicit contraindications to the endovascular treatment procedure
- Pregnancy
- Other serious, progressive, or end-stage diseases (as determined by the investigator) or a life expectancy of less than 6 months
- Attempted use of a neurothrombectomy device to remove the clot prior to randomization
- Currently participating in a study involving other investigational drugs or devices
- Evidence of intracranial tumor on CT or MRI (excluding meningioma)
- CTA/MRA showing excessive tortuosity of the cervical vessels, which may interfere with endovascular treatment
- Suspicion of aortic dissection based on medical history and CTA/MRA findings
- Any other conditions that the investigator believes may interfere with the endovascular procedure or pose significant risk to the subject during the procedure
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430000
Bo Hu, +86 13707114863, hubo@mail.hust.edu.cn
About this study
Official title: Endovascular Treatment for Posterior Circulation Ischemic Stroke Post 1 Day （24 Hours） A Randomized Controlled Clinical Trial On Efficacy
To evaluate the efficacy and safety of endovascular therapy for posterior circulation ischemic stroke presenting more than 24 hours after symptom onset.
Read the detailed description
This study is a multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy and safety of endovascular treatment administered beyond 24 hours after the onset of posterior circulation ischemic stroke. A total of 244 patients (122 per group) will be enrolled, aged ≥18 years, with a baseline NIHSS score ≥4, onset of stroke or last known well time >24 hours and within 14 days, and confirmed occlusion of the basilar artery or the intracranial segment of bilateral vertebral arteries as the culprit vessel. Patients will be randomly assigned to the experimental group (endovascular treatment plus standard medical therapy) or the control group (standard medical therapy alone). The primary endpoint is the proportion of patients with a 90-day modified Rankin Scale (mRS) score of 0-3. Secondary endpoints include the distribution of 90-day mRS scores, the proportion of patients with a 90-day mRS score of 0-2, and the 90-day EQ-5D-5L scale score. The study is led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as the coordinating center and will be conducted at multiple centers across China, with a planned duration of 36 months.
- Conditions
- Posterior Circulation Ischemic Stroke
- Being tested
- Endovascular treatment combined with standard pharmacological treatment, Standard pharmacological treatment
- Keywords
- stroke, Posterior Circulation
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endovascular treatment combined with standard pharmacological treatmentProcedure or surgery
Mechanical thrombectomy (stent retriever or aspiration) plus standard medical therapy (antiplatelet, statin, and risk factor control), specifically for posterior circulation stroke with onset >24 h to ≤14 days.
Standard pharmacological treatmentDrug
Standard medical therapy: antiplatelet, statin, and vascular risk factor control per stroke guidelines, without endovascular intervention.
| Study group | Role | What they receive |
|---|---|---|
| control group | Other | Standard pharmacological treatment Receives: Drug: Standard pharmacological treatment |
| Test group | Experimental | Endovascular treatment combined with standard pharmacological treatment Receives: Procedure: Endovascular treatment combined with standard pharmacological treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients with an mRS score of 0-3 at 90 days
Measured: 90days
Secondary outcomes (9)
Symptomatic intracranial hemorrhage (sICH) (defined as a worsening of NIHSS by 4 or more points within 24 hours after random treatment, associated with intracranial hemorrhage)
Measured: 24hours
Surgical-related complications
Measured: Post procedure 24hours
Stroke-related mortality at 90 days
Measured: 90days
EQ-5D-5L scale score at 90 days
Measured: 90days
New onset of stroke within 90 days
Measured: 90days
Hematoma of any type at 24 hours (-6/+24) after random treatment
Measured: 24hours
The distribution of mRS scores at 90 days post-randomization
Measured: 90days
All-cause mortality at 90 days
Measured: 90days
Proportion of patients with an mRS score of 0-2 at 90 days
Measured: 90days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2026
- Study start16 Jul 2026 (estimated)
- Primary completion1 Aug 2029 (estimated)
- Study completion1 Aug 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Posterior Circulation Ischemic StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 244 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hu Bo, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07699029
- Sponsor's protocol ID
- ETP1-PC
- Acronym
- ETP1-PC
- Status last verified
- Jul 2026
- First submitted
- 7 Jul 2026
- Last updated
- 30 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No